| Targeting the androgen receptor signaling pathway in advanced prostate cancer C Chung, K Abboud American Journal of Health-System Pharmacy 79 (15), 1224-1235, 2022 | 14 | 2022 |
| Pancreatic tumorigenesis: Precursors, genetic risk factors and screening M Badheeb, A Abdelrahim, A Esmail, G Umoru, K Abboud, E Al-Najjar, ... Current Oncology 29 (11), 8693-8719, 2022 | 10 | 2022 |
| Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future directions, and role in transplant oncology K Abboud, G Umoru, A Esmail, A Abudayyeh, N Murakami, HO Al-Shamsi, ... Cancers 15 (5), 1433, 2023 | 8 | 2023 |
| Antibiotic irrigation solutions for prevention of surgical site infections: A call to action K Abboud, J Blee, PJ Shah American Journal of Health-System Pharmacy 77 (24), 2040-2041, 2020 | 7 | 2020 |
| Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries British Journal of Surgery 111 (1), znad330, 2024 | 4 | 2024 |
| Sequencing and combination of current small‐molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence? C Chung, G Umoru, K Abboud, E Hobaugh European Journal of Haematology 111 (1), 15-28, 2023 | 3 | 2023 |
| Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics K Abboud, G Umoru, B Trachtenberg, V Ajewole Cardio-Oncology 10 (1), 22, 2024 | 1 | 2024 |
| The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma A Esmail, J Xu, EA Burns, K Abboud, A Sheikh, G Umoru, K Gee, ... Journal of Clinical Medicine 13 (17), 4994, 2024 | | 2024 |
| Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments D Bugazia, E Al-Najjar, A Esmail, S Abdelrahim, K Abboud, A Abdelrahim, ... Frontiers in Oncology 14, 2024 | | 2024 |
| Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma A Abudayyeh, A Esmail, A Kaseb, J Xu, K Abboud, G Umoru, ... HPB 25, S321, 2023 | | 2023 |
| Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma A Abudayyeh, A Esmail, A Kaseb, J Xu, G Umoru, K Abboud, ... HPB 25, S321-S322, 2023 | | 2023 |
Godsfavour UmoruHouston Methodist HospitalVerified email at houstonmethodist.org
